Latest Breaking News On - Company us securities - Page 1 : comparemela.com

ASLAN Pharmaceuticals : Amendment to Loan Agreement with K2 HealthVentures LLC - Form 6-K

ASLAN Pharmaceuticals : Amendment to Loan Agreement with K2 HealthVentures LLC - Form 6-K
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Cayman islandsUnited statesKiran kumar asarpotaCompany annual report on formPharmaceuticals pteExchange commission onHealthventures equity trustCompany us securitiesPharmaceuticals united states incAnkura trust companyCommission file noCompany registration statement on formSecurities exchangeSloan partyCayman islands the companyExchange commission

Volaris Reports Financial Results for the First Quarter

MEXICO CITY, April 22, 2024 (GLOBE NEWSWIRE) Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (NYSE: VLRS and BMV: VOLAR) (“Volaris” or “the.

Mexico cityDistrito federalUnited statesRicardo martEnrique beltranenaCompany us securitiesInternational financial reporting standardsPratt whitneyExchange commissionUs securities exchangeVuela compaSouth americaChief executive officerNew engine optionNew yorkControladora vuela compa

Volaris Reports Financial Results for the First Quarter 2024: Net Income of USD $33 million

Volaris Reports Financial Results for the First Quarter 2024: Net Income of USD $33 million
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Mexico cityDistrito federalUnited statesContactricardo martEnrique beltranenaUs securities exchangePratt whitneyCompany us securitiesExchange commissionInternational financial reporting standardsVuela compaSouth americaChief executive officerOperating highlightsNew engine optionRelations contactricardo mart

Controladora Vuela Compañía de Aviación B de C : Volaris Reports Financial Results for the First Quarter 2024

Volaris Reports Financial Results for the First Quarter 2024: Net Income of USD $33 million Mexico City, Mexico, April 22, 2024 -.

United statesMexico cityDistrito federalEnrique beltranenaRicardo martInternational financial reporting standardsPratt whitneyUs securities exchangeCompany us securitiesExchange commissionVolaris reports financial resultsNet incomeVuela compaSouth americaChief executive officerOperating highlights

ASLAN PHARMACEUTICALS : ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 2 STUDY OF EBLASAKIMAB IN DUPILUMAB-EXPERIENCED ATOPIC DERMATITIS PATIENTS - Form 6-K

ASLAN PHARMACEUTICALS ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 2 STUDY OF EBLASAKIMAB IN DUPILUMAB-EXPERIENCED ATOPIC DERMATITIS PATIENTS - Interim readout.

United statesCarl firthEmma thompsonAshleyr robinsonCompany us securitiesSpurwing communicationsPharmaceuticals nasdaqCompany annual report on formCommission file noExchange commissionExchange commission onLifesci advisorsEczema area severity indexChief executive officerNorth americaInvestigator global assessment